SBIR/STTR Recipient

Acrigen Biosciences, Inc.

Brief Description

Acrigin Biosciences is developing Precision Gene Editing Systems to harness the power of CRISPR for use in human therapeutics. Acrigen’s proprietary technology leverages novel αCas and μCas CRISPR gene editors coupled with ErAcrs (engineered anti-CRISPR proteins) to create an editing toolbox with best-in-class efficiency and precision. The company's technology will expand the impact of CRISPR by improving the efficacy and safety of novel gene editing therapies.

Timeline 2019. Company founded Inventors

Jennifer Doudna, Christof Fellmann, Haridha...

Acacia Biosciences, Inc.

Brief Description

Acacia Biosciences, Inc. was a drug discovery technology company committed to the creation of proprietary assay systems and databases that facilitate the rapid development of biopharmaceutical s and agricultural chemicals. The Genome Reporter Matrix is the first in a series of novel tools that provide practical analysis of early stage chemicals by interpreting their effects across entire genomes. In addition to the GRM, Acacia's technology is used to discover novel targets and gene regulatory mechanisms.

Acacia Biosciences merged with Rosetta Inpharmatics in 1999...